Gastroesophageal reflux disease (GERD) is estimated to affect nearly 20% of Americans. Recent advances in our understanding of GERD have changed clinical practice. Therefore, in February 2022, the American College of Gastroenterology (ACG) released an updated set of guidelines for the diagnosis and management of GERD. Research from Baylor University Medical Center (Baylor Dallas), part of Baylor Scott & White Health, helped shape these new practice guidelines.
An estimated 3 million individuals in the U.S. live with a condition called atrial fibrillation, or AFib, with some estimates projecting that number being closer to 6 million when taking unknown and undiagnosed cases into account.
Baylor Scott & White Research Institute (BSWRI) is well known for its diverse research portfolio. The program actively maintains nearly 2,000 active and enrolling projects across more than 50 medical specialties each year, including initiatives supported by its translational research program. The program is focused on driving innovation by working with clinical teams across the Baylor Scott & White Health System to develop new medicines and diagnostic tests. The translational research team’s approach to discovery of “bench-to-bedside- and- back-to-bench” allows BSWRI to continue to be a major contributor to advancements in medical science.
The extracorporeal membrane oxygenation (ECMO) program at Baylor Scott & White All Saints Medical Center – Fort Worth celebrated survivorship with joy, hope and fellowship at the ECMO Reunion on January 6. The event brought together ECMO patients and families from all over Texas to reunite with the physicians and staff members who made recovery possible.
ECMO technology provides advanced support for critically ill heart and lung patients, allowing time to recover or as a short-term bridge to transplant. Baylor Scott & White – Fort Worth is one of only three locations within the Baylor Scott & White system that offers ECMO capabilities. Since the ECMO program began at the hospital, over 200 patients have received this life-changing support.
Since 2019, the Advanced Heart and Lung Disease Center at Baylor Scott & White All Saints Medical Center – Fort Worth has offered a specialized approach to managing patients with heart failure. While the center provides options for heart failure in its most advanced stage, it also focuses on preventing the progression of the condition.
Baylor Scott & White Heart and Vascular Hospital – Fort Worth is actively recruiting for a study of cardiac contractility modulation (CCM) in a new group of heart failure patients. The AIM HIGHer study will evaluate the efficacy and safety of implantable CCM therapy in those with symptomatic heart failure and an ejection fraction (EF) between 40 and 60%.
The Valve Disorders Center at Baylor Scott & White Heart and Vascular Hospital – Fort Worth offers streamlined access to experts in valve disease for physicians and their patients. By bringing together a dedicated team from multiple specialties, including cardiothoracic surgeons on the medical staff of Baylor Scott & White All Saints Medical Center – Fort Worth, patients with valve disorders get a comprehensive evaluation and access to innovative treatments in one place.
The vascular program at Baylor Scott & White All Saints Medical Center – Fort Worth recently performed Tarrant County’s first fenestrated abdominal aortic aneurysm surgery, or FEVAR.
